Viibryd vs Trintellix: Food Rule, Side Effects, Differences

Viibryd (vilazodone) and Trintellix (vortioxetine) are the two newest “beyond-SSRI” antidepressants approved solely for major depressive disorder, and both add extra serotonin receptor activity to standard reuptake inhibition. But they differ sharply in one everyday practical rule: Viibryd must be taken with food or it may not work properly, while Trintellix can be taken with or without food. They also differ in which side effect dominates (diarrhea versus nausea) and in how much comparative evidence exists for reduced sexual side effects.

This is general information, not medical advice. Both are prescription antidepressants that require a prescriber’s guidance to start, adjust, or stop.

Viibryd vs Trintellix at a glance

	Viibryd (vilazodone)	Trintellix (vortioxetine)
Class	SSRI + 5-HT1A partial agonist (SPARI)	Multimodal serotonergic antidepressant (SERT inhibition + 5 other receptor activities)
FDA-approved for	MDD only	MDD only
Food requirement	Must be taken with food; without food, exposure drops ~50-60%	No food requirement
Dominant side effect	Diarrhea (~28%), nausea (~23%)	Nausea (dose-related, 15-20% in week one)
Titration	10 mg to 20 mg to 40 mg over 3 weeks	10 mg, increased to 20 mg as tolerated
Sexual side effect evidence	Limited direct comparative data	Direct study found superior to escitalopram on all sexual phases
Cognitive claim	None	FDA label includes processing-speed data
Approved since	2011	2013

The core similarity: added serotonin receptor activity

Both drugs go beyond a standard SSRI’s single mechanism. Viibryd’s label describes it as an SSRI plus a 5-HT1A receptor partial agonist. Trintellix’s label describes SERT inhibition plus activity at five additional serotonin receptor subtypes (5-HT3, 5-HT1D, 5-HT7 antagonism; 5-HT1B partial agonism; 5-HT1A agonism). Both labels use nearly identical cautious language: the exact contribution of these added mechanisms to the antidepressant effect is not established. Neither drug has been proven more effective for depression overall because of its extra mechanism; the added activity is better understood as shaping side-effect patterns than as boosting efficacy.

The food rule: the biggest everyday difference

This is the single most consequential practical difference. Viibryd’s absolute bioavailability is 72% with food, and without food its peak concentration and total exposure can fall by roughly 60% and 50% respectively, to the point that the label warns this can result in inadequate drug concentrations, meaning a dose taken on an empty stomach may simply not work as intended.

Trintellix carries no such requirement: its label specifically states it is taken orally once daily without regard to meals.

If your schedule makes consistent meal timing difficult, that alone may be reason enough to favor Trintellix over Viibryd, independent of any other consideration.

Side effects: diarrhea vs nausea

Viibryd’s defining side effects are gastrointestinal, and diarrhea specifically: 28% of patients in trials, alongside nausea (23%), insomnia (6%), and vomiting (5%).

Trintellix’s defining side effect is nausea, which is dose-related, most intense in the first one to two days, more common in women, usually mild to moderate, and has a median duration of about two weeks. Constipation and vomiting are the other most common adverse reactions.

Both patterns reflect each drug’s serotonergic activity in the gut, where a large share of the body’s serotonin receptors are located, which is why both cause prominent GI symptoms even though the specific symptom differs (diarrhea for Viibryd, nausea and constipation for Trintellix).

Sexual side effects: a real evidence gap

This is worth being precise about, since online claims often blur it. For Trintellix, real comparative data exists: a 2022 study found vortioxetine specifically superior to escitalopram across all measured sexual phases (desire, arousal, orgasm), and the Trintellix label describes prospective studies assessing sexual dysfunction, including in patients who had treatment-emergent sexual dysfunction from a prior SSRI.

For Viibryd, no comparably rigorous head-to-head sexual-function data against a standard SSRI, let alone against Trintellix specifically, has been established with the same strength. Claims that Viibryd causes fewer sexual side effects rest more on its added mechanism being theoretically similar to drugs where the effect has been shown, not on direct proof for vilazodone itself. If reduced sexual side effects are a priority, the current evidence favors Trintellix having actual comparative support, while Viibryd’s advantage in this area remains unproven relative to standard SSRIs and specifically relative to Trintellix.

Dosing

Viibryd: 10 mg once daily with food for 7 days, then 20 mg once daily with food for 7 days, then 40 mg once daily with food as the maintenance target. Food is required at every dose.

Trintellix: 10 mg once daily, without regard to meals, increased to 20 mg/day as tolerated; 5 mg/day can be considered for those who do not tolerate higher doses; capped at 10 mg/day in known CYP2D6 poor metabolizers.

Drug interactions

Trintellix requires halving the dose when combined with a strong CYP2D6 inhibitor (bupropion, fluoxetine, paroxetine, quinidine are named examples), since CYP2D6 is its primary clearance pathway.

Viibryd’s label notes its removal by dialysis has not been studied and, given its high volume of distribution, is expected to be ineffective, a relevant fact in any overdose scenario, though this is a different kind of consideration than a routine dosing interaction.

Both drugs carry the standard antidepressant-class interactions: contraindicated with MAOIs, elevated serotonin syndrome risk with other serotonergic drugs, and increased bleeding risk with NSAIDs, aspirin, and anticoagulants. Both carry the boxed warning for increased suicidal thoughts and behaviors in patients under 25.

What “SPARI” and “multimodal” mean in practice

These labels can sound like marketing jargon, so it helps to translate them into what a patient actually experiences.

SPARI (Viibryd) means the drug does two things: blocks serotonin reuptake like a normal SSRI, and also partially activates one specific serotonin receptor subtype (5-HT1A). In practice, this shows up mainly as a distinctive gastrointestinal side-effect pattern (heavy on diarrhea) and a strict food requirement tied to how the drug is absorbed, rather than as a clearly proven efficacy or tolerability advantage over standard SSRIs.

Multimodal (Trintellix) means the drug blocks serotonin reuptake and also interacts with five additional serotonin receptor subtypes in different ways (blocking three, partially activating one, fully activating another). In practice, this shows up as a nausea-dominant side-effect pattern, no food requirement, and two specific evidence-backed advantages: less sexual dysfunction than escitalopram in a direct study, and an FDA-recognized processing-speed benefit in acute depression.

Neither label term should be read as “this drug works better.” Both are approved based on placebo-controlled trials establishing that they work better than nothing for MDD, the same bar every antidepressant must clear. The distinguishing details are in side effects, practical dosing rules, and drug interactions, which is why this comparison focuses there rather than on efficacy rankings.

A note on cost and formulation

Both Viibryd and Trintellix remain more expensive than long-generic SSRIs like sertraline, escitalopram, or fluoxetine, since both are newer branded drugs, though generic vilazodone has become available. Insurance coverage and step-therapy requirements (insurers often requiring a trial of a cheaper generic SSRI first) frequently shape which of these two, if either, ends up being prescribed and covered. Ask your pharmacist about current generic availability and your specific insurance formulary, since this changes over time and varies by plan.

Who each might suit

Factors that may point toward Trintellix:

• Irregular eating patterns that make Viibryd’s strict food rule impractical
• Prominent cognitive symptoms of depression (slowed thinking), given its specific processing-speed label data
• A priority on minimizing sexual side effects, where real comparative evidence exists
• Concern about diarrhea specifically, since nausea (Trintellix’s main issue) is generally considered easier for most patients to tolerate long-term than persistent diarrhea

Factors that may point toward Viibryd:

• Reliable, consistent meal timing that makes the food rule easy to follow
• A history of tolerating nausea poorly but diarrhea reasonably, the reverse GI preference
• No strong CYP2D6-interacting medicines, simplifying dosing compared with Trintellix in that specific scenario

Frequently asked questions

Which is newer, Viibryd or Trintellix?

Viibryd was approved in 2011; Trintellix followed in 2013.

Do I have to eat with every dose of Viibryd?

Yes. The label states that administration without food can result in inadequate drug concentrations, meaning the dose may not work properly. This is not true of Trintellix, which can be taken with or without food.

Which causes more nausea, Viibryd or Trintellix?

Both can cause nausea, but Viibryd’s trials showed a similar or slightly higher combined GI burden (28% diarrhea plus 23% nausea) compared with Trintellix’s nausea-dominant profile (15-20% in week one, easing over about two weeks).

Is Trintellix better for sexual side effects than Viibryd?

There is real comparative evidence that vortioxetine causes fewer sexual side effects than escitalopram specifically. No equally strong comparative evidence exists for vilazodone against a standard SSRI or against vortioxetine directly, so any advantage for Viibryd in this area is less well established.

Can either drug improve thinking or focus?

Trintellix’s label includes trial data on improved processing speed in acute major depressive disorder specifically. Viibryd’s label makes no comparable claim.

Are Viibryd and Trintellix SSRIs?

Both include serotonin reuptake inhibition as part of their mechanism, but both are typically classified separately from standard SSRIs because of their added receptor activities (a SPARI for Viibryd, a multimodal antidepressant for Trintellix).

References

• FDA. VIIBRYD (vilazodone hydrochloride) tablets, full prescribing information (2017).
• FDA. TRINTELLIX (vortioxetine) prescribing information (2023).
• Takeda. TRINTELLIX prescribing information now includes new data showing improvement in processing speed (May 2018).
• Antidepressants and sexual dysfunction: is vortioxetine different? SAGE journals, 2022.
• Drugs.com. Vilazodone vs vortioxetine comparison.